Amra Kajdic

Amra Kajdic

Auto-generated profile, based on publicly available information

Amra Kajdic

National Human Genome Research Institute, Bethesda, Maryland, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Blood Advances
Verified
Journal Article
Open access
AKAmra Kajdic
Amra Kajdic
NDNatalie Deuitch
Natalie Deuitch
EBErica Bresciani
Erica Bresciani
SCShawn N Chong
Shawn N Chong
KCKathleen Marie Craft
Kathleen Marie Craft
PLPaul P Liu
Paul P Liu
Deleterious germ line RUNX1 variants cause familial platelet disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet dysfunction, and predisposition to hematologic malignancies (HM). We examined clinical and laboratory findings of pediatric (<19 years) patients with RUNX1-FPDMM enrolled in the National Institutes of Health RUNX1 Natural History Study. Pediatric patients have thrombocytopenia (131 ± 49 ×103/μL vs 314 ± 55 ×103/μL) and mild eosinophilia (372 ± 244/μL vs 165 ± 100/μL) similar to adults. Abnormal bleeding is less frequent in children than adults (32% vs 42%). Of 213 patients with RUNX1-FPDMM, 31 developed HM (13 pediatric, 19 adult; 1 had second malignancy). Lifetime HM risk is 42% (26%-55%). Median age of HM diagnosis is 36 years (range, 1-74). Pediatric patients have a 7.3% (3.5%-11%) cumulative incidence by age 18 years, 57.7-fold (27.7-86.6) higher than the general population, and are 3.4-fold more likely to develop HM by age 5 years than patients with Fanconi anemia. Unlike adult patients whose HM were all myeloid, pediatric patients develop a spectrum of HM but with a myeloid excess compared with the general pediatric population (62% vs 24%). Pediatric RUNX1-FPDMM HM is less likely than adult to have multiple somatic mutations (22% vs 67%), but more likely to have chromosome changes (67% vs 47%). We recommend prompt, universal cascade RUNX1 testing following a new diagnosis, regardless of age. Upon diagnosis, management of pediatric RUNX1-FPDMM should include a baseline bone marrow biopsy, once clinically acceptable, and peripheral blood evaluations. We recommend routine monitoring with quarterly blood counts and annual biopsy to monitor for changes and HM transformation. This trial was registered www.clinicaltrials.gov as #NCT03854318.

26 January 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
AKAmra Kajdic
Amra Kajdic
NDNatalie T. Deuitch
Natalie T. Deuitch
EBErica Bresciani
Erica Bresciani
JDJoie Davis
Joie Davis
KCKathleen Craft
Kathleen Craft
PLPaul Liu
Paul Liu

29 May 2025 in British Journal of Haematology
Verified
Journal Article
Open access
NDNatalie Deuitch
Natalie Deuitch
LHLylach Haizler‐Cohen
Lylach Haizler‐Cohen
AKAmra Kajdic
Amra Kajdic
EBErica Bresciani
Erica Bresciani
KCKathleen Craft
Kathleen Craft
PLP. Paul Liu
P. Paul Liu

4 August 2025 in Blood Neoplasia
Verified
Journal Article
Open access
AKAmra Kajdic
Amra Kajdic
NDNatalie Deuitch
Natalie Deuitch
AMAna Catarina Menezes
Ana Catarina Menezes
MKMartha Kirby
Martha Kirby
UHUrsula Harper
Ursula Harper
PLPaul P. Liu
Paul P. Liu